Launch of DelveInsight’s Antibody-Drug Conjugate Report
DelveInsight’sAntibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain. The Report provides the marketed and pipeline scenario of the ADCs. The Report has covered the 264 Antibody-drug conjugates profile which gives core information of the targets, mechanism of action, development partner, Technology partner, monoclonal antibody used, linker used and cytotoxic drug with the descriptive information of the technologies. The Report also provides the assessment of the company’s undergone collaborations for technology and monoclonal antibody and also gives insights over the pre-clinical and clinical data. The Report has also assessed the ADCs on geographical distribution based on the country and region.
Around 253 ADCs in Oncology
Antibody-Drug Conjugates are getting researched mostly for cancers. Cancer being the highest research area, there are 253 ADCs currently in pipeline. There are other companies which is also researching the ADC for different therapeutic areas like dermatology, immunology, women’s health, gastrointestinal and ophthalmology.
Four Potential ADCs in Phase III Pipeline
Companies are trying its already marketed ADC for different combinations and for different indications like Roche, Seattle Genetics conducting total 9 trials on their ADCs trastzumab emantisine and Brentuximab Vedotin. There are two new ADCs AstraZeneca’s Moxetumomab Pasudotox and Pfizer’s Inotuzumab Ozogamicin for Relapsed/ Refractory Hairy Cell Leukemia and Acute Lymphoblastic Leukemia respectively.